News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardiovascular BioTherapeutics, Inc. (CVBT.OB)'s Pharmacoeconomics Strategy Recognized in Nature Biotechnology Magazine


2/14/2008 8:54:22 AM

LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) has been recognized in an article in the February 2008 issue of Nature Biotechnology Magazine for its progressive development of a pharmacoeconomic strategy for the commercialization of its drug candidate CVBT-141H. The drug, which is moving into a US FDA approved Phase II clinical trial, treats severe coronary heart disease (CHD) and contains the active pharmaceutical ingredient (API) human fibroblast growth factor-1 (FGF-1).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES